Unlike previous therapies, sotatercept does not target the vascular tone, but partially restores the BMPR2/TGF‐β signaling imbalance and appears to be involved in reversing the remodeling seen in PAH (Preston et al. 2024). This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.